CA2125673A1 - Dna structure-specific recognition protein and uses therefor - Google Patents

Dna structure-specific recognition protein and uses therefor

Info

Publication number
CA2125673A1
CA2125673A1 CA002125673A CA2125673A CA2125673A1 CA 2125673 A1 CA2125673 A1 CA 2125673A1 CA 002125673 A CA002125673 A CA 002125673A CA 2125673 A CA2125673 A CA 2125673A CA 2125673 A1 CA2125673 A1 CA 2125673A1
Authority
CA
Canada
Prior art keywords
specific recognition
recognition protein
dna structure
dna
uses therefor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002125673A
Other languages
French (fr)
Other versions
CA2125673C (en
Inventor
Brian A. Donahue
Jeffrey H. Toney
John M. Essigmann
Stephen J. Lippard
Pieter M. Pil
Suzanne L. Bruhn
Steven J. Brown
Patti J. Kellett
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Massachusetts Institute of Technology
Original Assignee
Brian A. Donahue
Jeffrey H. Toney
John M. Essigmann
Stephen J. Lippard
Pieter M. Pil
Suzanne L. Bruhn
Steven J. Brown
Patti J. Kellett
Massachusetts Institute Of Technology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Brian A. Donahue, Jeffrey H. Toney, John M. Essigmann, Stephen J. Lippard, Pieter M. Pil, Suzanne L. Bruhn, Steven J. Brown, Patti J. Kellett, Massachusetts Institute Of Technology filed Critical Brian A. Donahue
Publication of CA2125673A1 publication Critical patent/CA2125673A1/en
Application granted granted Critical
Publication of CA2125673C publication Critical patent/CA2125673C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C07K14/43563—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from insects
    • C07K14/43577—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from insects from flies
    • C07K14/43581—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from insects from flies from Drosophila
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/142—Toxicological screening, e.g. expression profiles which identify toxicity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Abstract

DNA structure specific recognition protein of eukaryotic origin and DNA
encoding such a factor, as well as probes specific for DNA structure specific recognition protein or DNA encoding it and methods of detecting DNA structure specific recognition protein in eukaryotic cells. In particular, a mammalian cellular factor that selectively recognize and binds DNA damaged or modified by a drug (the anticancer drug, cis-diaminedichloroplatinum (II) or cisplatin) has been identified.
CA002125673A 1991-12-26 1992-12-18 Dna structure-specific recognition protein and uses therefor Expired - Fee Related CA2125673C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US07/814,964 US5359047A (en) 1988-09-22 1991-12-26 Nucleic acids encoding DNA structure-specific recognition protein and uses therefor
US814,964 1991-12-26
PCT/US1992/011107 WO1993013222A1 (en) 1991-12-26 1992-12-18 Dna structure-specific recognition protein and uses therefor

Publications (2)

Publication Number Publication Date
CA2125673A1 true CA2125673A1 (en) 1993-07-08
CA2125673C CA2125673C (en) 2001-03-13

Family

ID=25216483

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002125673A Expired - Fee Related CA2125673C (en) 1991-12-26 1992-12-18 Dna structure-specific recognition protein and uses therefor

Country Status (7)

Country Link
US (2) US5359047A (en)
EP (1) EP0621902B1 (en)
JP (1) JPH07502415A (en)
AT (1) ATE182628T1 (en)
CA (1) CA2125673C (en)
DE (1) DE69229681T2 (en)
WO (1) WO1993013222A1 (en)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5705334A (en) 1988-09-22 1998-01-06 Massachusetts Institute Of Technology Uses for DNA structure-specific recognition protein
US5874218A (en) * 1990-06-11 1999-02-23 Nexstar Pharmaceuticals, Inc. Method for detecting a target compound in a substance using a nucleic acid ligand
US5874283A (en) * 1995-05-30 1999-02-23 John Joseph Harrington Mammalian flap-specific endonuclease
US5912332A (en) * 1996-07-26 1999-06-15 Hybridon, Inc. Affinity-based purification of oligonucleotides using soluble multimeric oligonucleotides
US6030783A (en) * 1997-01-31 2000-02-29 Massachusetts Institute Of Technology Photo-potentiation of cisplatin chemotherapy
US6166194A (en) * 1998-06-29 2000-12-26 Myriad Genetics, Inc. TMPRSS2 is a tumor suppressor
US7960540B2 (en) 1999-04-08 2011-06-14 Advanced Cancer Therapeutics, Llc Antiproliferative activity of G-rich oligonucleotides and method of using same to bind to nucleolin
US20080318890A1 (en) * 1999-04-08 2008-12-25 Antisoma Research Limited Antiproliferative activity of G-rich oligonucleotides and method of using same to bind to nucleolin
US8114850B2 (en) 1999-04-08 2012-02-14 Advanced Cancer Therapeutics, Llc Antiproliferative activity of G-rich oligonucleotides and method of using same to bind to nucleolin
JP2002541264A (en) 1999-04-08 2002-12-03 ユーエイビー・リサーチ・ファウンデーション Anti-proliferative activity of G-rich oligonucleotide and its use for binding to nucleolin
US20080318889A1 (en) * 1999-04-08 2008-12-25 Antisoma Research Limited Antiproliferative activity of G-rich oligonucleotides and method of using same to bind to nucleolin
EP1229934B1 (en) 1999-10-01 2014-03-05 Immunogen, Inc. Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
US6573050B1 (en) 1999-10-29 2003-06-03 Sunnybrook & Women's College Health Sciences Centre Treatment, diagnosis and evaluation of anti-cancer therapy resistance in melanoma
FR2809417B1 (en) * 2000-05-24 2004-07-30 Commissariat Energie Atomique DETECTION AND CHARACTERIZATION OF PROTEIN ACTIVITY INVOLVED IN THE REPAIR OF DNA INJURIES
DE10030452A1 (en) * 2000-06-21 2002-01-24 Max Planck Gesellschaft In vitro detection of DNA damage, useful e.g. for determining genotoxicity of chemicals, comprises measuring specific interaction between DNA and repair proteins
US6806289B1 (en) 2000-07-14 2004-10-19 Stephen J. Lippard Coordination complexes, and methods for preparing by combinatorial methods, assaying and using the same
EP1412746A4 (en) * 2001-07-12 2007-08-08 Exelixis Inc HADHs AS MODIFIERS OF THE P21 PATHWAY AND METHODS OF USE
ITTO20010762A1 (en) * 2001-07-31 2003-01-31 Consiglio Nazionale Ricerche ANTI-SSRP-1 MONOCLONAL ANTIBODIES AND HYBRIDS PRODUCING SUCH ANTIBODIES.
JP4007000B2 (en) * 2001-12-25 2007-11-14 富士ゼロックス株式会社 Conductive organic polymer
CA2473642A1 (en) * 2002-01-25 2003-08-07 Sheikh Ismail Electrophoretic assay to predict risk of cancer and the efficacy and toxicity of cancer therapy
US7153691B2 (en) * 2002-11-13 2006-12-26 G6 Science Corp. Method of identifying and assessing DNA euchromatin in biological cells for detecting disease, monitoring wellness, assessing bio-activity, and screening pharmacological agents
US20090148958A1 (en) * 2006-04-27 2009-06-11 Onecell Inc. Nucleotide-transition metal complex catalyst

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4407942A (en) * 1981-01-29 1983-10-04 Atomic Energy Of Canada Limited Fluorescent detection of DNA damage
US4670388A (en) * 1982-12-30 1987-06-02 Carnegie Institution Of Washington Method of incorporating DNA into genome of drosophila
JPS6343931A (en) * 1986-08-12 1988-02-25 Diafoil Co Ltd Polyester film for magnetic recording medium
WO1990003396A1 (en) * 1988-09-22 1990-04-05 Massachusetts Institute Of Technology Dna damage-binding factor and uses therefor

Also Published As

Publication number Publication date
WO1993013222A1 (en) 1993-07-08
EP0621902A1 (en) 1994-11-02
DE69229681T2 (en) 2000-04-06
ATE182628T1 (en) 1999-08-15
US5359047A (en) 1994-10-25
CA2125673C (en) 2001-03-13
EP0621902B1 (en) 1999-07-28
US5670621A (en) 1997-09-23
DE69229681D1 (en) 1999-09-02
JPH07502415A (en) 1995-03-16

Similar Documents

Publication Publication Date Title
CA2125673A1 (en) Dna structure-specific recognition protein and uses therefor
ATE353906T1 (en) CD27 LIGAND
NO301829B1 (en) 2-pyridylmethylene polyazamacrocyclophosphonic acids, complexes and pharmaceutical preparations based on these
WO2000050088A3 (en) Biotinylated-chemokine antibody complexes
WO1997040854A3 (en) Polypeptide conjugates for transporting substances across cell membranes
FR2707433B1 (en) Card connector, in particular for electronic card.
CA2413156A1 (en) Expression vectors
WO1989003041A3 (en) Tridentate conjugate and method of use thereof
EP0640409A3 (en) Small flats sorter.
LV11429A (en) Tricyclopiazamacrocyclophosphonates for complexes and derivatives for use as contrast media
NZ335485A (en) Isolated nucleic acid molecule encoding cancer associated antigen, the antigen itself, and uses thereof
DE69433552D1 (en) CYTOKIN BINDING TO THE HEK CELL SURFACE RECEPTOR
DE69021417T2 (en) Passenger transportation facility.
RU94009852A (en) Mutants of tumor factor necrosis
CA2067250A1 (en) Inhibition of padgem-mediated cell binding
WO1997029199A3 (en) Prostate specific antigen peptides and uses thereof
ZA975588B (en) Isolated nucleic acid molecules which code for gage tumor rejection antigen, the tumor rejection antigen, and uses thereof.
MX9602557A (en) Proteins from mammalian liver and their use in oncology.
EP0669396A4 (en) Novel polypeptide and dna coding for the same.
EP0328495A3 (en) System for the safe and secure transportation of valuable articles, such as bank notes, cheques etc.
CA2197651A1 (en) Or-1 on orphan receptor belonging to the nuclear receptor family
CA2115151A1 (en) Tau/neurofilament protein kinases pk40 and pk36
CA2199403A1 (en) Novel PKA-Binding Proteins and Uses Thereof
CA2080408A1 (en) Artificial standard and control sera, processes for the preparation thereof and the use thereof
AU2622188A (en) Containers, e.g. beach bags

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed